SPOTLIGHT: FDA approves Noxafil

The FDA has approved Noxafil, Schering-Plough's therapy for preventing fungal infections in leukemia patients. The infections-candida and aspergillus-are the leading cause of death among leukemia patients receiving chemotherapy or stem cell transplant therapies. Report

Suggested Articles

The FDA slapped a partial clinical hold on the phase 2/3 study of Inovio’s COVID-19 vaccine because it has “additional questions” about the trial.

Preclinical inflammatory disease biotech Ilias Biologics has grabbed a $20.6 million funding round as it eyes a 2021 human test of its leading asset.

Aligos Therapeutics is shooting for a $100 million IPO to help drive its early work on a functional cure for chronic hepatitis B as well as COVID-19.